
Carotuximab Combo Proves Safe for Advanced Prostate Cancer
Carotuximab (ENV-105) was well tolerated when combined with the standard of care hormone therapy, Erleada (apalutamide), in the first 10 patients enrolled on a phase 2 trial for metastatic castration-resistant prostate cancer in; no serious side effects …